Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
Front Immunol. 2023 Feb 7;14:942849. doi: 10.3389/fimmu.2023.942849. eCollection 2023.
Secretory pathway kinase or kinase-like proteins (SPKKPs) are effective in the lumen of the endoplasmic reticulum (ER), Golgi apparatus (GA), and extracellular space. These proteins are involved in secretory signaling pathways and are distinctive from typical protein kinases. Various reports have shown that SPKKPs regulate the tumorigenesis and progression of human cancer the phosphorylation of various substrates, which is essential in physiological and pathological processes. Emerging evidence has revealed that the expression of SPKKPs in human cancers is regulated by multiple factors. This review summarizes the current understanding of the contribution of SPKKPs in tumorigenesis and the progression of immunity. With the epidemic trend of immunotherapy, targeting SPKKPs may be a novel approach to anticancer therapy. This study briefly discusses the recent advances regarding SPKKPs.
分泌途径激酶或激酶样蛋白 (SPKKPs) 在内质网 (ER) 腔、高尔基体 (GA) 和细胞外空间中都很有效。这些蛋白参与分泌信号通路,与典型的蛋白激酶不同。各种报告表明,SPKKPs 通过对各种底物的磷酸化调节人类癌症的发生和发展,这在生理和病理过程中是必不可少的。新出现的证据表明,SPKKPs 在人类癌症中的表达受到多种因素的调节。这篇综述总结了目前对 SPKKPs 在肿瘤发生和免疫进展中的作用的认识。随着免疫疗法的流行趋势,针对 SPKKPs 可能是一种新的抗癌治疗方法。本研究简要讨论了 SPKKPs 的最新进展。